« Previous article
The Devil in the Det...

6th October 2021  Content supplied by: Test&Treat Ltd

Novel, Rapid, Point-of-Care Technology Enables Fast, Effective and Responsible Antibiotic Choice


Test and Treat has launched a novel Point of Care technology that identifies bacterial infection and a quantitative antibiotic susceptibility profile in less than 2 hours. The first application is Urinary Tract Infection (UTI)). Using this novel phenotypic technology, physicians/veterinarians can prescribe treatment in line with best practice, without having to rely on empirical prescribing and/or wait several days for external laboratory culture and sensitivity. U-Treat provides a valuable tool for fast, reliable, Point-of-Care treatment outcomes.

Launched globally in late 2020, U-Treat is already used by veterinary practices in the US and UK. Using the principles of ATP bioluminescence, U-Treat can both detect (directly) the presence of bacteria within 30 minutes (Test 1) and determine quantitative antibiotic susceptibility in an additional 60 minutes (Test 2). The tests are run sequentially. Results give clinicians clear guidance about whether or not antibiotic treatment is required, and – if it is – the most effective antibiotic to prescribe, based on a determination of " % kill rate per antibiotic".

Ron Turner, Founder, CEO, and Technical Director says, "We know antimicrobial resistance (AMR) is increasing and is described by many governments as a global crisis. This technology can help physicians and veterinarians make fast, effective and responsible decisions in antibiotic choice and prescribing, and improve treatment outcomes."

Test&Treat is fast moving towards CE/CA marking for UK and European regulatory compliance, is also working towards US FDA regulatory approval (510k/CLIA waiver), and is now actively seeking licensing / acquisition partners in veterinary and human diagnostics to fast-track the technology into markets worldwide.

U-Treat demonstrates high levels of sensitivity (97.1%) and specificity (92%), compared to laboratory-reported test results (UTI detection). The test provides confidence in diagnosis and treatment outcome while observing responsible use of antibiotics. Pet owners and physicians in the human sector can be reassured treatment is based on quantitative antibiotic susceptibility/resistance, rather than empirical. The test is currently validated for use in companion animals and is being investigated for application for mastitis in cattle and sheep, bacterial infection in equine synovial fluid, interstitial and pleural fluid, bacterial ear infections and for UTI, bacterial throat infection, synovial fluid, and bacterial meningitis in human healthcare.

For more information, visit www.tandtreat.com or contact the supplier with the green "Request Information" button below.


    

Tags:

Date Published: 6th October 2021

Source article link: View


View full company details